Clinical Trial: Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed

Brief Summary: This randomized phase III trial studies how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumors that have returned after a period of improvement or did not respond to treatment. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as filgrastim or pegfilgrastim, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. It is not yet known whether high-dose combination chemotherapy and stem cell transplant are more effective than standard-dose combination chemotherapy in treating patients with refractory or relapsed germ cell tumors.

Detailed Summary:

The study is an international collaboration with European sites. Collaborators on the study include the National Cancer Institute, the European Organization for Research and Treatment of Cancer and the Movember Foundation. Randomization will be stratified by region (North America and Europe) and by modified IPFSG (International Prognostic Factor Study Group) risk classification (low, intermediate and high). The primary and secondary objectives are described below.

Primary Objective:

1. To compare the overall survival in patients treated with conventional-dose chemotherapy using the TIP regimen with high-dose chemotherapy (HDCT) plus autologous stem cell transplant (ASCT) using the TI-CE regimen as initial salvage treatment of patients with relapsed or refractory germ cell tumors (GCT)

Secondary Objectives:

  1. To compare the progression-free survival (PFS) of patients treated with initial salvage HDCT with TI-CE versus initial salvage CDCT with TIP
  2. To compare the favorable response rate (FRR) of patients treated with initial salvage HDCT with TI-CE versus initial salvage CDCT with TIP
  3. To compare the toxicity, including treatment-related mortality, associated with high-dose chemotherapy and ASCT using TI-CE compared with conventional-dose chemotherapy using TIP as initial salvage treatment for patients with relapsed or refractory GCT
  4. To prospectively evaluate the IPFSG scoring system as a predictor of outcome to initial salvage therapy in patients with relapsed or refractory GCT. In this trial, randomization will be stratified by a modification of their IPFSG category and we will prospectively e
    Sponsor: Alliance for Clinical Trials in Oncology

    Current Primary Outcome: overall survival [ Time Frame: Up to 36 months post-treatment ]

    Original Primary Outcome: Same as current

    Current Secondary Outcome:

    • progression free survival [ Time Frame: Up to 36 months post-treatment ]
    • proportion of patients achieving either a complete response (CR) or partial response [ Time Frame: Up to 3 months post-registration ]
    • treatment related mortality [ Time Frame: Up to 30 days post-treatment ]
    • number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: Up to 3 months post-registration ]
    • Validation of International Prognostic Factor Study Group stratification system (eg, primary site, prior response, progression free interval) [ Time Frame: Up to 3 years post-registration ]


    Original Secondary Outcome:

    • progression free survival [ Time Frame: Up to 36 months post-treatment ]
    • proportion of patients achieving either a complete response (CR) or parital response [ Time Frame: Up to 3 months post-registration ]
    • treatment related mortality [ Time Frame: Up to 30 days post-treatment ]
    • toxicity [ Time Frame: Up to 3 months post-registration ]


    Information By: Alliance for Clinical Trials in Oncology

    Dates:
    Date Received: February 20, 2015
    Date Started: March 2015
    Date Completion:
    Last Updated: April 19, 2017
    Last Verified: April 2017